U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07281716) titled 'Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC' on Nov. 25.
Brief Summary: Phase 1b/2 open-label study evaluates the safety, tolerability, and efficacy of combination immunotherapy with nadunolimab (anti-IL-1RAP) and toripalimab (anti-PD-1) in patients with chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal cancer. Phase 1b will assess dose-limiting toxicity (DLT), while Phase 2 will evaluate objective response rate (ORR), including progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). Exploratory analyses ...